secwatch.observer — SEC 8-K summary
======================================

Issuer:     FILANA THERAPEUTICS, INC. (FLNA)
CIK:        0001069530
Form:       8-K
Filed at:   2025-08-04T23:59:59+00:00
Accession:  0001171843-25-004981
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud

Cassava Sciences Reports Positive Preclinical Results for Simufilam in TSC-Related Epilepsy Model
--------------------------------------------------------------------------------

- Simufilam attenuated seizure progression with significant dose-response in Tsc1 conditional knockout mouse model of TSC-related epilepsy.
- Study conducted in collaboration with TSC Alliance and TSC Preclinical Consortium, executed by PsychoGenics, Inc.
- First clinical proof-of-concept study for simufilam in TSC-related epilepsy is expected to begin in H1 2026.
- Results consistent with prior findings published in Science Translational Medicine from Yale School of Medicine.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1069530/000117184325004981/0001171843-25-004981-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1069530/000117184325004981/f8k_080425.htm
  HTML page:      https://secwatch.observer/filing/0001171843-25-004981

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer